The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The molecular genetics of gastroenteropancreatic neuroendocrine tumors
Open accessAbstract
The pathobiology of neuroendocrine tumors (NETs) is hampered by the lack of scientific tools that define their mechanisms of secretion, proliferation, and metastasis; and, currently, there are no accurate means to assess tumor behavior and disease prognosis. Molecular biologic techniques and genetic analysis may facilitate the delineation of the molecular pathology of NETs and provide novel insights into their cellular mechanisms. The current status and recent advances in assessment of the molecular basis of tumorigenesis of gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) were reviewed (1981–2004). The objectives of this retrospective study were to provide a cohesive overview of the current state of knowledge and to develop a molecular understanding of these rare tumor entities to facilitate the establishment of therapeutic targets and rational management strategies. Multiple differences in chromosomal aberration patterns were noted between gastrointestinal (GI) neuroendocrine and pancreatic endocrine tumors (PETs). Divergence in gene expression patterns in the development of GI carcinoids and PETs was identified, whereas examination of the PET and GI carcinoid data demonstrated only few areas of overlap in the accumulation of genetic aberrations. These data suggest that the recent World Health Organization classification of GEP‐NETs may require updating. In addition, previous assumptions of tumor similarity (pancreatic vs. GI) may be unfounded when they are examined at a molecular level. On the basis of the evolution of genetic information, enteric neuroendocrine lesions (carcinoids) and PETs may need to be classified as two distinct entities rather than grouped together as the single entity “GEP‐NETs.” Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337 · cited 2×
“DPC4/Smad4 DPC4/Smad4, which is involved in transcriptional regulation, is located at 18q21.(61) In 8 midgut carcinoids, sequencing of this gene failed to reveal any mutations in the DPC4/Smad4 gene, whereas 88% of tumors had LOH on chromosome 18.”
BackgroundIdentification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648 · cited 1×
“3, encode the proteins harmatin and tuberin.(23,24) Studies in TSC-associated tumors, including astrocytomas(25) and hamartomas,(26) have indicated LOH at these locations, suggesting a possible tumor suppressor role for these genes.”
BackgroundIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
β-catenin: a key mediator of Wnt signaling
Willert, K., & Nusse, R. (1998) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(98)80068-3 · Cited by 753
Ras‐related proteins in signal transduction and growth control
McCormick, F. (1995) · Molecular Reproduction and Development · doi:10.1002/mrd.1080420419 · Cited by 115
Cited by
The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
Lawrence, B., Gustafsson, B. I., Chan, A., Svejda, B., Kidd, M., & Modlin, I. M. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.12.005 · Cited by 861
Self-citationRoldo, C., Missiaglia, E., Hagan, J. P., Falconi, M., Capelli, P., Bersani, S., Calin, G. A., Volinia, S., Liu, C.-G., Scarpa, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.5194 · Cited by 775
Neuroendocrine tumor epidemiology: Contrasting Norway and North America
Hauso, O., Gustafsson, B. I., Kidd, M., Waldum, H. L., Drozdov, I., Chan, A. K. C., & Modlin, I. M. (2008) · Cancer · doi:10.1002/cncr.23883 · Cited by 505
Self-citationPancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors
Halfdanarson, T. R., Rubin, J., Farnell, M. B., Grant, C. S., & Petersen, G. M. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0221 · Cited by 372
The genomic landscape of small intestine neuroendocrine tumors
Banck, M. S., Kanwar, R., Kulkarni, A. A., Boora, G. K., Metge, F., Kipp, B. R., Zhang, L., Thorland, E. C., Minn, K. T., Tentu, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67963 · Cited by 324
Metadata
- Authors
- Zikusoka, M. N., Kidd, M., Eick, G., Latich, I., & Modlin, I. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-10-28
- Volume
- 104
- Issue
- 11
- Pages
- 2292-2309
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2094629870
- Cited by
- 163
- References
- 6
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.